Literature DB >> 23527996

The Ludwig institute for cancer research Melbourne melanoma cell line panel.

Andreas Behren1, Matthew Anaka, Pu-Han Lo, Laura J Vella, Ian D Davis, Jenny Catimel, Tracy Cardwell, Craig Gedye, Christopher Hudson, Rodica Stan, Jonathan Cebon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23527996     DOI： 10.1111/pcmr.12097

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  30 in total

Review 1.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

2.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Authors:  Marian L Burr; Christina E Sparbier; Yih-Chih Chan; James C Williamson; Katherine Woods; Paul A Beavis; Enid Y N Lam; Melissa A Henderson; Charles C Bell; Sabine Stolzenburg; Omer Gilan; Stuart Bloor; Tahereh Noori; David W Morgens; Michael C Bassik; Paul J Neeson; Andreas Behren; Phillip K Darcy; Sarah-Jane Dawson; Ilia Voskoboinik; Joseph A Trapani; Jonathan Cebon; Paul J Lehner; Mark A Dawson
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

3.  Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.

Authors:  Prashanth Prithviraj; Matthew Anaka; Sonja J McKeown; Michael Permezel; Marzena Walkiewicz; Jonathan Cebon; Andreas Behren; Aparna Jayachandran
Journal:  Oncotarget       Date:  2015-06-30

4.  Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.

Authors:  Simon Chang-Hao Tsao; Jonathan Weiss; Christopher Hudson; Christopher Christophi; Jonathan Cebon; Andreas Behren; Alexander Dobrovic
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

5.  FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.

Authors:  BeeShin Tan; Matthew Anaka; Siddhartha Deb; Claudia Freyer; Lisa M Ebert; Anderly C Chueh; Sheren Al-Obaidi; Andreas Behren; Aparna Jayachandran; Jonathan Cebon; Weisan Chen; John M Mariadason
Journal:  Oncotarget       Date:  2014-01-15

6.  Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Authors:  Stephen Q Wong; Andreas Behren; Victoria J Mar; Katherine Woods; Jason Li; Claire Martin; Karen E Sheppard; Rory Wolfe; John Kelly; Jonathan Cebon; Alexander Dobrovic; Grant A McArthur
Journal:  Oncotarget       Date:  2015-01-20

7.  Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.

Authors:  Leona Rohrbeck; Jia-Nan Gong; Erinna F Lee; Andrew J Kueh; Andreas Behren; Lin Tai; Guillaume Lessene; David C S Huang; Walter D Fairlie; Andreas Strasser; Marco J Herold
Journal:  Cell Death Differ       Date:  2016-09-30       Impact factor: 15.828

8.  Differential antigenic requirements by diverse MR1-restricted T cells.

Authors:  Rebecca Seneviratna; Samuel J Redmond; Hamish Eg McWilliam; Rangsima Reantragoon; Jose A Villadangos; James McCluskey; Dale I Godfrey; Nicholas A Gherardin
Journal:  Immunol Cell Biol       Date:  2022-01-13       Impact factor: 5.853

Review 9.  Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine.

Authors:  Hyun Seok Kim; Yeo-Jin Sung; Soonmyung Paik
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759

10.  A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells.

Authors:  Ramakrishna Sompallae; Oliver Hofmann; Christopher A Maher; Craig Gedye; Andreas Behren; Morana Vitezic; Carsten O Daub; Sylvie Devalle; Otavia L Caballero; Piero Carninci; Yoshihide Hayashizaki; Elizabeth R Lawlor; Jonathan Cebon; Winston Hide
Journal:  Front Genet       Date:  2013-10-29       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.